Skip to main content
. 2024 Jan 11;47(4):580–588. doi: 10.2337/dc23-1070

Table 1.

Selected baseline phenotypic and metabolic characteristics

All participants (N = 4,801) Insulin glargine U-100 (N = 1,210) Glimepiride (N = 1,215) Liraglutide (N = 1,148) Sitagliptin (N = 1,228) P
Age (years) 57.1 ± 10.0 57.0 ± 9.8 57.0 ± 10.0 57.2 ± 9.9 57.3 ± 10.1 0.840
n women (%) 1,736 (36.2) 432 (35.7) 462 (38.0) 387 (33.7) 455 (37.1) 0.148
Race, n (%) 0.221
 All others 688 (14.3) 166 (13.7) 170 (14.0) 171 (14.9) 181 (14.7) 0.326
 Black 933 (19.4) 233 (19.3) 262 (21.6) 222 (19.3) 216 (17.6)
 White 3,180 (66.2) 811 (67.0) 783 (64.4) 755 (65.8) 831 (67.7)
Hispanic ethnicity, n (%) 872 (18.3) 209 (17.4) 227 (18.9) 206 (18.0) 230 (18.9) 0.740
Duration of diabetes (years) 4.2 ± 2.7 4.2 ± 2.7 4.3 ± 2.8 4.2 ± 2.7 4.2 ± 2.7 0.527
Weight (kg) 100.2 ± 22.2 100.8 ± 22.3 99.6 ± 22.4 101.1 ± 22.7 99.4 ± 21.4 0.159
BMI (kg/m2) 34.3 ± 6.8 34.4 ± 6.8 34.3 ± 6.8 34.5 ± 6.7 34.1 ± 6.7 0.573
HbA1c (%) 7.5 ± 0.5 7.5 ± 0.5 7.5 ± 0.5 7.5 ± 0.5 7.5 ± 0.5 0.621
HbA1c (mmol/mol) 58.4 ± 5.3 58.4 ± 5.2 58.2 ± 5.2 58.5 ± 5.4 58.5 ± 5.3 0.621
Fasting plasma glucose (mg/dL) 151.9 ± 30.9 153.1 ± 32.0 151.5 ± 31.1 151.7 ± 30.7 151.4 ± 29.6 0.495
Fasting plasma C-peptide (nmol/L) 0.8 ± 0.5 0.8 ± 0.5 0.7 ± 0.5 0.7 ± 0.5 0.8 ± 0.5 0.558
HOMA2-%S (C-peptide) 34.1 ± 15.5 33.8 ± 15.2 34.3 ± 15.9 34.1 ± 15.8 34.2 ± 15.4 0.831
HOMA2-%B (C-peptide) 85.6 ± 35.0 84.8 ± 35.0 85.9 ± 35.2 85.8 ± 34.6 86.0 ± 35.5 0.820
CPI 0.8 ± 0.5 0.8 ± 0.5 0.7 ± 0.5 0.7 ± 0.5 0.8 ± 0.5 0.558
Total C-peptide response 1.0 ± 0.6 1.0 ± 0.6 1.1 ± 0.6 1.0 ± 0.6 1.1 ± 0.6 0.533

Continuous variables are summarized as mean ± SD. Categorical variables are summarized as counts and column percentages. The P values are based on ANOVA F tests for continuous variables and χ2 tests for binary and categorical variables. CPI was calculated as 100(C30 − C0)/(G30 − G0) and total C-peptide response as 100 × (C-peptide incAUC0–120/(glucose incAUC0–120).